CN115917313A - 非放射性物质标记的药剂的药代动力学的测定方法 - Google Patents

非放射性物质标记的药剂的药代动力学的测定方法 Download PDF

Info

Publication number
CN115917313A
CN115917313A CN202180049693.1A CN202180049693A CN115917313A CN 115917313 A CN115917313 A CN 115917313A CN 202180049693 A CN202180049693 A CN 202180049693A CN 115917313 A CN115917313 A CN 115917313A
Authority
CN
China
Prior art keywords
labeled
drug
mass spectrometry
plasma
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180049693.1A
Other languages
English (en)
Chinese (zh)
Inventor
南部健
尾关和久
高野阳子
渡边美穗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN115917313A publication Critical patent/CN115917313A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202180049693.1A 2020-07-29 2021-07-29 非放射性物质标记的药剂的药代动力学的测定方法 Pending CN115917313A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-128088 2020-07-29
JP2020128088 2020-07-29
PCT/JP2021/028099 WO2022025184A1 (ja) 2020-07-29 2021-07-29 非放射性物質で標識した薬剤の薬物動態を測定する方法

Publications (1)

Publication Number Publication Date
CN115917313A true CN115917313A (zh) 2023-04-04

Family

ID=80036342

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049693.1A Pending CN115917313A (zh) 2020-07-29 2021-07-29 非放射性物质标记的药剂的药代动力学的测定方法

Country Status (5)

Country Link
US (1) US20230296612A1 (https=)
EP (1) EP4190801A4 (https=)
JP (1) JPWO2022025184A1 (https=)
CN (1) CN115917313A (https=)
WO (1) WO2022025184A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031503A1 (en) * 2003-09-08 2007-02-08 Chugai Seiyaku Kabushiki Kaisha Hyaluronic acid modification products and drug carrier therefrom
DE102012104504A1 (de) * 2012-05-24 2013-11-28 Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Wirtschaft und Technologie, dieses vertreten durch den Präsidenten der BAM, Bundesanstalt für Materialforschung und -prüfung Polypeptidmarker

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
JP4585069B2 (ja) 1999-12-27 2010-11-24 アジレント・テクノロジーズ・インク 誘導結合プラズマ質量分析装置及び方法
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
EP1348127B1 (en) * 2000-12-28 2008-12-17 MDS Inc., doing business as MDS Sciex Elemental analysis of tagged biologically active materials
US7700295B2 (en) 2000-12-28 2010-04-20 Mds Sciex Elemental analysis of tagged biologically active materials
US20060051851A1 (en) 2001-09-13 2006-03-09 Sara Kaminaka Novel selenocysteine-containing protein
WO2003048207A2 (en) * 2001-11-28 2003-06-12 Immunomedics, Inc. Anti-dota antibody
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
JP2007228824A (ja) * 2006-02-28 2007-09-13 Dai Ichi Seiyaku Co Ltd 薬物相互作用の検討方法
AU2014259570B2 (en) * 2007-12-19 2016-06-09 Immunomedics, Inc. Improved methods and compositions for F-18 labeling of proteins, peptides and other molecules
KR20230143201A (ko) 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
JP7073250B2 (ja) 2016-03-03 2022-05-23 中外製薬株式会社 チオール基をアミノ基近傍に有するアミノ酸をｎ末端に持つ非環状ペプチド－核酸複合体、そのライブラリー、およびそれから誘導される環状ペプチド－核酸複合体ライブラリーの製造方法
MA48861A (fr) * 2017-05-05 2020-04-01 Fusion Pharmaceuticals Inc Améliorations pharmacocinétiques de chélates bifonctionnels et leurs utilisations
JP7482630B2 (ja) 2017-11-28 2024-05-14 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
CN111228521B (zh) * 2020-01-17 2021-03-19 中国科学院生物物理研究所 一种Dar2多肽放射性药物及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031503A1 (en) * 2003-09-08 2007-02-08 Chugai Seiyaku Kabushiki Kaisha Hyaluronic acid modification products and drug carrier therefrom
DE102012104504A1 (de) * 2012-05-24 2013-11-28 Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Wirtschaft und Technologie, dieses vertreten durch den Präsidenten der BAM, Bundesanstalt für Materialforschung und -prüfung Polypeptidmarker

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOROS, E.: "Metabolite profiling with HPLC-ICP-MS as a tool for in vivo characterization of imaging probes", EJNMMI RADIOPHARM. CHEM., vol. 3, 22 January 2018 (2018-01-22), pages 1 - 10 *
李好枝: "体内药物分析", vol. 2, 31 August 2011, 中国医药科技出版社, pages: 110 - 113 *

Also Published As

Publication number Publication date
EP4190801A1 (en) 2023-06-07
US20230296612A1 (en) 2023-09-21
JPWO2022025184A1 (https=) 2022-02-03
EP4190801A4 (en) 2024-10-02
WO2022025184A1 (ja) 2022-02-03

Similar Documents

Publication Publication Date Title
JP7682553B2 (ja) 癌の処置
JP2023078366A (ja) ポリペプチドの放射性標識
EP3470418B1 (en) Site-specific radioisotope-labeled antibody using igg-binding peptide
JP2012528601A (ja) ＩｇＧ結合のための部位を同定するための方法
WO2022162549A2 (en) Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
JP2021504695A (ja) リガンド−薬物複合体を分析するための酸媒介アッセイ
Sharma et al. Synthesis and comparative in vivo evaluation of site-specifically labeled radioimmunoconjugates for DLL3-targeted immunoPET
WO2023231889A1 (zh) 一种抗体缀合物及其应用
Postupalenko et al. Template directed synthesis of antibody Fc conjugates with concomitant ligand release
Cahuzac et al. Monitoring in vivo performances of protein–drug conjugates using site-selective dual radiolabeling and ex vivo digital imaging
US11236386B2 (en) Method for labeling of aldehyde containing target molecules
CN115917313A (zh) 非放射性物质标记的药剂的药代动力学的测定方法
BR112019011304A2 (pt) anticorpo monoclonal, método de medição de substâncias a analisar em amostras, uso, kit de teste de imunoensaio, imunogene da fórmula i e métodos de produção de anticorpos
HK40089934A (zh) 非放射性物质标记的药剂的药代动力学的测定方法
JP7834710B2 (ja) ポリペプチド免疫原性を予測するためのｔ細胞ベースの方法
AU2023242087A1 (en) Method for producing complex
US20250163101A1 (en) Method for increasing production yield of antibody-drug conjugate by using thiol-reactive additive
CN111212850B (zh) 关于抗体的复制保护
HK40085873A (en) T cell-based methods for predicting polypeptide immunogenicity
CN119978125A (zh) 核素标记的抗Trop2单域抗体
JP2023554258A (ja) 新規のポリペプチド
EA045797B1 (ru) Радиоактивное мечение полипептидов
HK40014589B (zh) 睫状神经营养因子受体配体结合剂及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40089934

Country of ref document: HK